>
Genetic Technologies logo

GTG - Genetic Technologies Share Price

A$0.008 -0.0  -16.7%

Last Trade - 5:05am

Sector
Healthcare
Size
Micro Cap
Market Cap £34.1m
Enterprise Value £25.2m
Revenue £14.1k
Position in Universe 972nd / 1911
Bullish
Bearish
Unlock GTG Revenue
Momentum
Relative Strength (%)
1m -20.6%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -46.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2.01 0.82 0.52 0.19 0.025 0.010 -65.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, GeneticTechnologies Limited revenues increased from A$1K to A$16K.Net loss increased 31% to A$3.5M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Higher net lossreflects Selling and Marketing increase from A$277K toA$599K (expense), Other gains/(losses) - net decrease of92% to A$21K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

GTG Revenue Unlock GTG Revenue

Net Income

GTG Net Income Unlock GTG Revenue

Normalised EPS

GTG Normalised EPS Unlock GTG Revenue

PE Ratio Range

GTG PE Ratio Range Unlock GTG Revenue

Dividend Yield Range

GTG Dividend Yield Range Unlock GTG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
GTG EPS Forecasts Unlock GTG Revenue
Profile Summary

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated January 5, 1987
Public Since July 30, 1987
No. of Shareholders: n/a
No. of Employees: 64
Sector Healthcare
Industry Healthcare Providers & Services
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 8,261,726,743
Free Float (0.0%)
Eligible for
ISAs
SIPPs
GTG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for GTG
Upcoming Events for GTG
Frequently Asked Questions for Genetic Technologies
What is the Genetic Technologies share price?

As of 5:05am, shares in Genetic Technologies are trading at A$0.008, giving the company a market capitalisation of £34.1m. This share price information is delayed by 15 minutes.

How has the Genetic Technologies share price performed this year?

Shares in Genetic Technologies are currently trading at A$0.008 and the price has moved by 36.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Genetic Technologies price has moved by 2.06% over the past year.

What are the analyst and broker recommendations for Genetic Technologies?

Of the analysts with advisory recommendations for Genetic Technologies, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Genetic Technologies is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Genetic Technologies next release its financial results?

Genetic Technologies is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Genetic Technologies dividend yield?

Genetic Technologies does not currently pay a dividend.

Does Genetic Technologies pay a dividend?

Genetic Technologies does not currently pay a dividend.

When does Genetic Technologies next pay dividends?

Genetic Technologies does not currently pay a dividend.

How do I buy Genetic Technologies shares?

To buy shares in Genetic Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Genetic Technologies?

Shares in Genetic Technologies are currently trading at A$0.008, giving the company a market capitalisation of £34.1m.

Where are Genetic Technologies shares listed? Where are Genetic Technologies shares listed?

Here are the trading details for Genetic Technologies:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: GTG
What kind of share is Genetic Technologies?

Based on an overall assessment of its quality, value and momentum, Genetic Technologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Genetic Technologies share price forecast 2021?

We were not able to load any forecast data for Genetic Technologies.

How can I tell whether the Genetic Technologies share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genetic Technologies. Over the past six months, the relative strength of its shares against the market has been -7.63%. At the current price of A$0.008, shares in Genetic Technologies are trading at -15.09% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Genetic Technologies PE Ratio?

We were not able to find PE ratio data for Genetic Technologies.

Who are the key directors of Genetic Technologies?

Genetic Technologies's management team is headed by:

M. Luisa Ashdown - OTH
Mark Ostrowski - CEX
Richard Allman - OTH
Diana Newport - OTH
Lindsay Wakefield - NID
Susan Gross - OTH
Jerzy Muchnicki - EDR
Peter Rubenstein - CHM
Phillip Hains - CFO
Nick Burrows - NED
Stan Sack - COO
Simon Morriss - CEO
Who are the major shareholders of Genetic Technologies?

Here are the top five shareholders of Genetic Technologies based on the size of their shareholding:

Rubenstein (Peter Irwin) Individual Investor
Percentage owned: 3.42% (308.1m shares)
Muchnicki (Jerzy) Individual Investor
Percentage owned: 2.92% (263.1m shares)
Doma 193 Pty. Ltd. Corporation
Percentage owned: 1.6% (144.6m shares)
Intracoastal Capital, L.L.C. Corporation
Percentage owned: 0.92% (83.0m shares)
Hilcor Trading Pty. Ltd. Corporation
Percentage owned: 0.83% (75.0m shares)
Similar to GTG
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.